AbbVie said acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis is expected to be included in GAAP and adjusted non-GAAP results for Q3 2025, representing an unfavorable impact of $1.50 to both diluted earnings per share and adjusted non-GAAP diluted earnings per share.

1. 01

   AbbVie said acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis is expected to be included in GAAP and adjusted non-GAAP results for Q3 2025, representing an unfavorable impact of $1.50 to both diluted earnings per share and adjusted non-GAAP diluted earnings per share.

2. 02

   The company said its full-year 2025 adjusted diluted earnings per share guidance range, including the impact of Q3 acquired IPR&D and milestones expense, is $10.38 to $10.58. Previously announced guidance excluding this expense was $11.88 to $12.08; amounts other than EPS in the table are in millions.

3. 03

   AbbVie presented full-year 2025 acquired IPR&D and milestones expense of 3,751 million in the table (in millions), which reflects 2,680 million for Q3 added to the prior guidance of 1,071 million. The company said acquired IPR&D and milestones expense incurred beyond Q3 is excluded from guidance because it cannot be reliably forecasted.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.